GP
SCLN

GLG Partners’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

GLG Partners’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,586,437
Closed -$29M – 556
2017
Q3 		$29M Buy
2,586,437
+997,540
+63% +$11M 1.53% 9
2017
Q2 		$17.5M Buy
1,588,897
+1,225,709
+337% +$12.3M 0.97% 21
2017
Q1 		$3.56M Buy
363,188
+265,627
+272% +$2.65M 0.17% 174
2016
Q4 		$1.05M Buy
+97,561
New +$976K 0.04% 286

GLG Partners's SCLN Position: Q4 2017 in Review

GLG Partners sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 2,586,437 shares — an estimated $29M sold.

GLG Partners first reported a position in SCLN in Q4 2016 and held it in 4 quarters. The position peaked at $29M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • GLG Partners reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • GLG Partners sold 2,586,437 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $29M.
  • GLG Partners first reported a position in Sciclone Pharmaceuticals Inc in Q4 2016 and held it in 4 quarters.
  • GLG Partners's Sciclone Pharmaceuticals Inc position peaked at $29M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.